ArticleThe Clinical biochemist. Reviews2009
Clinical use of pharmacogenomic tests in 2009.
Article in The Clinical biochemist. Reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin.Cancer chemotherapy and pharmacology · 2024Article
- Genomic Interventions in Medicine.Bioinformatics and biology insights · 2018Review
- Design and evaluation of a pharmacogenomics information resource for pharmacists.Journal of the American Medical Informatics Association : JAMIA · 2017Article
- Documenting Pharmacogenomic Testing with CPT Codes.Journal of AHIMA · 2016Article
- Clinical applications of CYP genotyping in psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome.BMC research notes · 2012Article
- Construction of a drug safety assurance information system based on clinical genotyping.ISRN bioinformatics · 2012Article
- Hepatotoxic effects of therapies for tuberculosis.Nature reviews. Gastroenterology & hepatology · 2010Review
- Debating clinical utility.Public health genomics · 2010Article
- Planning for translational research in genomics.Genome medicine · 2009Article
- Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.Journal of the American Medical Informatics Association : JAMIAArticle
- Commentary: Children and predictive genomic testing: disease prevention, research protection, and our future.Journal of pediatric psychologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics is a new field where testing an individual can define either a risk status for an adverse event, or the rate of metabolism of a drug. This is achieved by the categorisation of the enzyme activity or documenting genetic polymorphisms of a metabolising enzyme. The best example of risk status assessment is the recent finding that HLA-B typing a person can predict whether they are at risk of a severe skin reaction from the drug abacavir. Those patients showing HLA-B*5701, who are being considered for abacavir therapy, can be prevented from developing potentially toxic epidermal necrosis (TEN) or Stevens-Johnson Syndrome by avoiding abacavir. The evidence for HLA-B typing for allopurinol and carbamazepine has also been described. Most other pharmacogenomic tests are of drug metabolising enzymes, which can either be assessed using "probe" drugs and measuring a ratio of parent drug to metabolite, or, by genetic testing for polymorphisms of the genes. In practice, testing is usually done by molecular testing, but this typically does not detect all polymorphisms. This article briefly reviews the evidence for the utilisation of pharmacogenomics for antidepressant drugs, tamoxifen, codeine, warfarin, azathioprine, clopidogrel, omeprazole, tacrolimus and irinotecan. There are few pharmacogenomics tests being carried out in practice, as there has not been a wide appreciation of their use, and only limited evidence exists for many individual drugs. It is expected that utilisation will increase as more evidence becomes available and there is a wider understanding of the existing evidence by the medical profession.
Identifiers
19565025PMC2702214W1530565236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.